Skip to main content
. 2022 Oct 26;20(1):245–253. doi: 10.1007/s13311-022-01305-9

Fig. 1.

Fig. 1

Longitudinal trends of clinical and fluid biomarkers in SMA children treated with nusinersen. Compared to older children (n = 4, dark blue), younger children (n = 9, light blue) had greater CHOP INTEND and CMAPAPB over time (*p < 0.005), but not CMAPADM and weight. In the CSF, levels of NfL, MCP-1, sAPPα, and sAPPβ declined in levels regardless of age, but levels of IL-8 and IP-10 only decreased in younger children (**p < 0.05)